Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737164 | 1.00 | BTK (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL5527336 | 1.00 | BTK (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL23048922 | 0.87 | KDM1A (0.45) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL22199165 | 0.86 | NFKB1 (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL2630501 | 0.86 | NFKB1 (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL2630499 | 0.86 | NFKB1 (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL25041953 | 0.85 | BTK (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL24831927 | 0.84 | BTK (0.44) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL15122679 | 0.84 | BTK (0.44) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL22680983 | 0.82 | DRD2 (0.44) | BTKNFKB1NFKB2RELAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11780801-B2 | Methods of synthesis of (1R,2R,5R)-5-amino-2-methyl-cyclohexanol hydrochloride and intermediates useful therein | CELGENE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780801-B2 | Methods of synthesis of (1R,2R,5R)-5-amino-2-methyl-cyclohexanol hydrochloride and intermediates useful therein | CELGENE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780801-B2 | Methods of synthesis of (1R,2R,5R)-5-amino-2-methyl-cyclohexanol hydrochloride and intermediates useful therein | CELGENE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11492332-B2 | Isotopologues of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220234990-A1 | METHODS OF SYNTHESIS OF (1R,2R,5R)-5-AMINO-2-METHYL-CYCLOHEXANOL HYDROCHLORIDE AND INTERMEDIATES USEFUL THEREIN | CELGENE CORP (US) | 2022-07-28 | — | — | US | disclosed |
| US-20220234990-A1 | METHODS OF SYNTHESIS OF (1R,2R,5R)-5-AMINO-2-METHYL-CYCLOHEXANOL HYDROCHLORIDE AND INTERMEDIATES USEFUL THEREIN | CELGENE CORP (US) | 2022-07-28 | — | — | US | disclosed |
| US-9365524-B2 | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365524-B2 | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150336901-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-26 | — | — | US | disclosed |
| US-9139534-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2015116755-A2 | SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150210650-A1 | SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE | SIGNAL PHARMACEUTICALS LLC | 2015-07-30 | — | — | US | disclosed |
| US-20150210650-A1 | SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE | SIGNAL PHARMACEUTICALS LLC | 2015-07-30 | — | — | US | disclosed |
| EP-2699553-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2013-01-31 | — | — | US | disclosed |
| WO-2012145569-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885NFKB1 483/4885NFKB2 444/4885 |
| US-20150210650-A1 | SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE | TERT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPMT | BTK 1729/4885NFKB1 2697/4885NFKB2 3807/4885 |
| US-11780801-B2 | Methods of synthesis of (1R,2R,5R)-5-amino-2-methyl-cyclohexanol hydrochloride and intermediates useful therein | MAPKAPK2, MAP3K8, MAPK1 | BTK 4303/4885NFKB1 933/4885NFKB2 1418/4885 |
| US-11492332-B2 | Isotopologues of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TERT, BRD4 | BTK 4416/4885NFKB1 3363/4885NFKB2 4401/4885 |
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885NFKB1 483/4885NFKB2 444/4885 |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885NFKB1 483/4885NFKB2 444/4885 |
| US-20150336901-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885NFKB1 483/4885NFKB2 444/4885 |
| US-20220234990-A1 | METHODS OF SYNTHESIS OF (1R,2R,5R)-5-AMINO-2-METHYL-CYCLOHEXANOL HYDROCHLORIDE AND INTERMEDIATES USEFUL THEREIN | MAPKAPK2, MAP3K8, MAPK1 | BTK 4303/4885NFKB1 933/4885NFKB2 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.